David Hafler (Yale School of Medicine, CT) considers recent developments in understanding of genetic risk, as well as the roles of regulatory T cells and B cells in multiple sclerosis (MS), and shares his view on what he considers to be the most important therapeutic targets in MS and remaining questions yet to be addressed.
1. To what extent do genetic variants drive the risk of MS? (0:11)
2. What has recent research taught us about the role of regulatory T cells in MS? (1:18)
3. How can these findings be used in the development of new therapies for MS? (2:13)
4. What do you consider the most important breakthrough in MS therapy in the last year? (2:54)
5. What do you consider to be the most urgent unmet need in MS at present? (3:53)
Speaker disclosure: David Hafler serves as a consultant to Compass Therapeutics, EMD Serono, and Merck Sharp & Dohme; is on scientific advisory boards for Genentech, MedImmune, and Mylan Pharmaceuticals; and has received research support/funding from Genentech and Bristol-Myers Squibb.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.
Share this Video
Related Videos In Multiple Sclerosis
Bernhard Hemmer, ECTRIMS 2021: Phase 3 Antelope Study Results Investigating Natalizumab Biosimilar PB006 in RMS
touchNEUROLOGY met up with Prof. Bernhard Hemmer (TUM-Klinikum rechts der Isar, Munich, Germany) to discuss the primary data from the phase III Antelope study, investigating proposed natalizumab biosimilar PB006 in relapsing remitting multiple sclerosis. The abstract entitled: ‘Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: primary […]
Le Hanh Hua, ECTRIMS 2021: Hot Topics in Multiple Sclerosis
touchNEUROLOGY joins Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the hot topics in the field of multiple sclerosis. The abstract entitled: ‘Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study’ was […]
Le Hanh Hua, ECTRIMS 2021: Siponimod’s Efficacy on Secondary Progressive MS – Post-hoc Analysis of the EXPAND Study
It was a pleasure to meet with Dr Le Hanh Hua (Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA) to discuss the use of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study. The abstract entitled: ‘Safety and efficacy of siponimod in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!